Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2025-12-25 @ 2:38 AM
NCT ID:
NCT02842034
Eligibility Criteria:
Inclusion Criteria:
* The diagnosis of schizophrenia according to DSM-IV；
* 18～55 years old；
* schizophrenic illness duration longer than one year;
* The sum of negative scores in the range Positive and negative symptom score (PANSS) must be 20 points or higher, at least one item from the area of negative symptoms (N1-N7) must be ≥ 4 points (at least moderate, clinically significant symptoms), and improvement in negative symptom-sum (measuring by PANSS) must be 10% or lower during the last two weeks before rTMS stimulation.
* Have a stable and consistent drug treatment at least two weeks prior the rTMS treatment;
* Able to adhere to the treatment schedule;
* IQ≥80;
* Dextromanual, normal vision and hearing;
* Signed an informed consent
Exclusion Criteria:
* rTMS contraindications: intracranial metal substance, with heart pacemakers and cochlear implants, intracranial pressure;
* Acute risk of suicide and impulse；
* patients to be diagnosed according to DSM-IV for substance abused, development delayed;
* suffering from serious physical disease and can not accept the treatment;
* history of epileptic seizures or the presence of epileptic activity documented on the basis of EEG;
* difficult to maintain the current drug treatment for at least 1 month;
* undergoing ECT or MECT in last 3 months;
* current treatment with anticonvulsant acting drugs such as anticonvulsants, benzodiazepines.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
15 Years
Maximum Age:
55 Years
Study:
NCT02842034
Study Brief:
Protocol Section:
NCT02842034